Digital Biology

Better measurements, better medicines

What is the Challenge?

Biological drugs have transformed medicine, offering limitless potential to engineer complex drug functions that complex diseases with cell, gene, and protein therapies. But the rapid pace of innovation in design has outstripped advancements in functional testing within human tissue models, leaving the opportunity largely untapped. Closing this gap requires precise preclinical models that predict human outcomes, and pairing these models with high-throughput measurements to test for complex tissue functions earlier in the drug discovery process. These advancements will accelerate the discovery and development of the next generation of transformative biological medicines.

What is the Solution?

Digital Biology has built a data engine to design and precisely screen biological drugs for translational functions, at scale. The company’s platform combines a new spatial sequencing technology with AI-lab automation and robust infrastructure to extract deeper molecular insights from patient tumors and preclinical models.

The platform repurposes photolithography—used in silicon chip manufacturing—to print DNA “GPS-tags” on biological molecules with sub-cellular precision, enabling accurate tracking of RNA within cells and correlating molecular states with tissue functions. By uniquely connecting molecular sequencing to tissue imaging at scale, Digital Biology’s platform delivers scalable molecular insights from human tumor biopsies to guide the development of predictive preclinical models, and accelerates functional screening of biological drugs for rapid iterations toward translational success.

Latest